Carvedilol and Ivabradine interacts in the following cases:
No dosage adjustment is required in patients with renal insufficiency and creatinine clearance above 15 mL/min and SBP >100 mmHg.
No data are available in patients with creatinine clearance below 15 mL/min. Carvedilol/ivabradine should be used with precaution in patients with creatinine clearance below 15 mL/min.
Monitoring of renal function is recommended in chronic heart failure patients with SBP <100 mmHg.
It may be necessary to adjust the dose in patients with mild to moderate hepatic impairment.
Caution should be exercised in patients with moderate hepatic impairment.
Based on existing data with the individual components, the use of carvedilol/ivabradine fixed-dose combination is contraindicated during pregnancy.
There are insufficient data on the use of carvedilol in pregnant women. Experimental animal studies have shown reproductive toxicity. The potential risk use in humans is unknown. Beta-blockers reduce placental perfusion which may result in intrauterine foetal death and immature and premature deliveries. In addition, adverse effects (especially hypoglycaemia and bradycardia, hypotension, respiratory depression and hypothermia) may occur in the foetus and neonate. There may be an increased risk of cardiac and pulmonary complications in the neonate during the postnatal period. There are no or limited amount of data from the use of ivabradine in pregnant women.
Animal studies with ivabradine have shown reproductive toxicity. These studies have shown embryotoxic and teratogenic effects. The potential risk for humans is unknown.
Carvedilol/ivabradine combination is contraindicated during breast-feeding.
Animal studies have shown that carvedilol or its metabolites are excreted in the breast milk. It is not known whether carvedilol is excreted in the human breast milk.
Animal studies indicate that ivabradine is excreted in milk. Women that need treatment with ivabradine should stop breast-feeding and choose for another way of feeding their child.
Women of child-bearing potential should use appropriate contraceptive measures during treatment.
There are no clinical data on fertility with the use of carvedilol/ivabradine.
Studies with carvedilol have shown impaired fertility in adult female rats. Studies in rats with ivabradine shown no effect on fertility in males and females.
Based on existing data with the individual components, the use of carvedilol/ivabradine fixed-dose combination may affect the ability to drive or use machinery.
Due to variability of individual reactions on carvedilol (such as dizziness, fatigue or decreased alertness), the ability to drive or operate machinery may be impaired. This is particularly true at the start of treatment, when the dose is increased, during the switch to a new preparation, or when taken together with alcohol.
Ivabradine may affect the patient’s ability to drive. Patients should be warned that ivabradine may cause transient luminous phenomena (consisting mainly of phosphenes). Luminous phenomena may occur in situations when there are sudden variations in light intensity, especially when driving at night. Ivabradine has no influence on the ability to use machines. However, in post-marketing experience, cases of impaired driving ability due to visual symptoms have been reported.
For carvedilol, the frequency of undesirable effects is not dose-dependent, with the exception of dizziness, visual disturbances and bradycardia.
For ivabradine, the most common adverse reactions, luminous phenomena (phosphenes) and bradycardia are dose-dependent and related to the pharmacological effect of the medicinal product.
The following undesirable effects have been observed during treatment with carvedilol and ivabradine given separately and ranked under the MedDRA classification by body system and under heading of frequency using the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
MedDRA System Organ Class | Undesirable effects | Frequency | |
---|---|---|---|
Carvedilol | Ivabradine | ||
Infections and infestations | Bronchitis | Common | - |
Pneumonia | Common | - | |
Upper respiratory tract infections | Common | - | |
Urinary tract infections | Common | - | |
Blood and lymphatic system disorders | Anaemia | Common | - |
Eosinophilia | - | Uncommon | |
Thrombocytopenia | Rare | - | |
Leukopenia | Very rare | - | |
Immune system disorders | Allergic reactions (hypersensitivity) | Very rare | - |
Metabolism and nutrition disorders | Hypercholesterolaemia | Common | - |
Deterioration in glycaemic control (hyperglycaemia or hypoglycaemia) in patients with pre-existing diabetes | Common | - | |
Diabetes mellitus | Common | - | |
Hyperuricaemia | - | Uncommon | |
Psychiatric disorders | Depressive mood, depression | Common | - |
Sleep disorders, nightmares | Uncommon | - | |
Confusion | Uncommon | - | |
Nervous system disorders | Headache | Very common | Common |
Dizziness | Very common | Common | |
Syncope | Uncommon | Uncommon | |
Presyncope | Uncommon | - | |
Paraesthesia | Uncommon | - | |
Eye disorders | Luminous phenomena (phosphenes) | - | Very Common |
Visual impairment | Common | Uncommon | |
Irritation of the eye | Common | - | |
Blurred vision | - | Common | |
Reduced lacrimation | Common | - | |
Diplopia | - | Uncommon | |
Ear and labyrinth disorders | Vertigo | - | Uncommon |
Cardiac disorders | Heart failure | Very common | - |
Bradycardia | Common | Common | |
Pulmonary oedema | Common | - | |
Oedema (including generalised and peripheral oedema and swelling of the genital area and feet, hypervolaemia and fluid retention) | Common | - | |
AV 1st degree block (ECG prolonged PQ interval) | - | Common | |
Ventricular extrasystoles | - | Common | |
Atrial fibrillation | - | Common | |
Angina pectoris | Uncommon | - | |
Palpitations | - | Uncommon | |
Supraventricular extrasystoles | - | Uncommon | |
AV-block | Uncommon | - | |
AV 2nd degree block | - | Very Rare | |
AV 3rd degree block | - | Very Rare | |
Sick sinus syndrome | - | Very Rare | |
Vascular disorders | Hypotension | Very common | Uncommon (possibly related to bradycardia) |
Postural hypotension | Common | - | |
Disturbances of peripheral circulation (cold extremities, PVD, exacerbation of intermittent claudication and Raynauds phenomenon) | Common | - | |
Uncontrolled blood pressure | - | Common | |
Respiratory, thoracic and mediastinal disorders | Dyspnoea | Common | Uncommon |
Asthma in predisposed patients | Common | - | |
Nasal congestion | Rare | - | |
Wheezing | Rare | - | |
Gastrointestinal disorders | Nausea | Common | Uncommon |
Diarrhoea | Common | Uncommon | |
Abdominal pain | Common | Uncommon* | |
Vomiting | Common | - | |
Dyspepsia | Common | - | |
Constipation | Uncommon | Uncommon | |
Dry mouth | Rare | - | |
Skin and subcutaneous tissue disorders | Skin reactions (such as allergic exanthema, dermatitis, urticaria, pruritus and increased sweating) | Uncommon | - |
Reactions similar to lichen planus, psoriasis or psoriasiform exanthema (occurring several weeks up to years after the start of treatment). Existing lesions may worsen. | Uncommon | - | |
Alopecia | Uncommon | - | |
Angioedema | - | Uncommon | |
Rash | - | Uncommon | |
Erythema | - | Rare | |
Pruritus | - | Rare | |
Urticaria | - | Rare | |
Severe skin reactions (such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis) | Very rare | - | |
Musculoskeletal and connective tissue disorders | Pain in extremities | Common | - |
Gout | Common | - | |
Muscle spasms | - | Uncommon | |
Renal and urinary disorders | Renal failure and renal function abnormality in patients with diffuse vascular disease and/or underlying renal insufficiency | Common | - |
Micturition disorders | Common | - | |
Urinary incontinence in women | Very rare | - | |
General disorders and administration site conditions | Asthenia, fatigue | Very common | Uncommon |
Pain | Common | - | |
Malaise (possibly related to bradycardia) | - | Rare | |
Investigations | Weight gain | Common | - |
Blood creatinine increased | - | Uncommon | |
ECG prolonged QT interval | - | Uncommon | |
Increase in the transaminases ALT, AST and GGT | Very rare | - | |
Reproductive system and breast disorders | Impotence, erectile dysfunction | Uncommon | - |
* Frequency calculated from clinical trials for adverse events detected from spontaneous report.
Dizziness, syncope, headache and debility are generally mild and are more likely to occur at the start of treatment.
Cardiac failure is an event commonly reported both in patients treated with placebo and in patients treated with carvedilol (14.5% and 15.4% respectively, in patients with left ventricular dysfunction following acute myocardial infarction).
A reversible deterioration in renal function has been observed during treatment with carvedilol in patients with chronic cardiac insufficiency with low blood pressure, ischaemic heart disease and diffuse vascular disease and/or basal renal insufficiency.
Non-selective beta-blockers in particular may cause latent diabetes to become manifest, manifest diabetes to be aggravated and blood glucose control to be impaired. The glucose balance may also be slightly upset during treatment with carvedilol, but this does not happen often.
Carvedilol may cause urinary incontinence in women. The problem is resolved once treatment is discontinued.
Luminous phenomena (phosphenes) were reported by 14.5% of patients, described as a transient enhanced brightness in a limited area of the visual field. They are usually triggered by sudden variations in light intensity. Phosphenes may also be described as a halo, image decomposition (stroboscopic or kaleidoscopic effects), coloured bright lights, or multiple images (retinal persistency). The onset of phosphenes is generally within the first two months of treatment after which they may occur repeatedly. Phosphenes were generally reported to be of mild to moderate intensity. All phosphenes resolved during or after treatment, of which a majority (77.5%) resolved during treatment. Fewer than 1% of patients changed their daily routine or discontinued the treatment in relation with phosphenes.
Bradycardia was reported by 3.3% of patients particularly within the first 2 to 3 months of treatment initiation. 0.5% of patients experienced a severe bradycardia below or equal to 40 bpm.
In the SIGNIFY study, atrial fibrillation was observed in 5.3% of patients taking ivabradine compared to 3.8% in the placebo group. In a pooled analysis of all the Phase II/III double blind controlled clinical trials with a duration of at least 3 months including more than 40,000 patients, the incidence of atrial fibrillation was 4.86% in ivabradine treated patients compared to 4.08% in controls, corresponding to a hazard ratio of 1.26, 95% CI [1.15-1.39].
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.